Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | Patient-reported outcomes of mevrometostat and enzalutamide in mCRPC

Neal Shore • 19 Oct 2025
ESMO 2025
Genitourinary Cancer Prostate Cancer Enzalutamide Mevrometostat

Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, comments on patient-reported outcomes from the Phase I study (NCT03460977) of mevrometostat plus enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). The combination maintained overall health-related quality of life, with a significant delay in time to deterioration on the prostate cancer-specific subscale. These findings support the tolerability of adding mevrometostat to standard therapy and are being further investigated in ongoing Phase III trials. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Neal Shore

EMBARK: long-term remissions with hormonal therapy in prostate cancer
1:44
EMBARK: long-term remissions with hormonal therapy in prostate cancer
Neal Shore • 26 Feb 2026
TulmiSTAR-02: tulmimetostat plus darolutamide or abiraterone in mHSPC
1:54
TulmiSTAR-02: tulmimetostat plus darolutamide or abiraterone in mHSPC
Neal Shore • 26 Feb 2026
177Lu-PSMA-617 after sipuleucel-T in mCRPC: PRECISION analysis
1:39
177Lu-PSMA-617 after sipuleucel-T in mCRPC: PRECISION analysis
Neal Shore • 26 Feb 2026
Assessing darolutamide and ADT safety vs other ARPIs in mCSPC
1:36
Assessing darolutamide and ADT safety vs other ARPIs in mCSPC
Neal Shore • 26 Feb 2026

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals